Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics: IKEMA Subgroup Analysis

Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.

Related Videos
Related Content